A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from COVID-19, the National Institutes of Health reports. The trial will enroll about 2,…
(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from coronavirus disease 201…
A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from coronavirus disease 2019 (COVID-19). The National Institute of Allergy and Infectio…
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Q4 2019 Acacia Research Corp Earnings Call
Acacia Research Corporation (NASDAQ: ACTG) announced today it will release its first quarter financial results on Monday, May 11, 2020 at 8:00 a.m. ET/ 5:00 a.m. PT.
In a randomized, controlled trial of 150 patients with mild to moderate COVID-19 in China, researchers found that patients on hydroxychloroquine did not get better significantly faster than those not treated with the drug. Adverse events were also higher in p…
Acacia Research Corporation ("we", "Acacia) (Nasdaq: ACTG) today provided an update on its investment in Immersion Corporation (Nasdaq: IMMR) ("Immersion") and its previous nomination of directors for election to the Board of Directors of Immersion (the "Board") .
Finding stocks with a negative enterprise value is an excellent way to find deep value Continue reading...
Q3 2019 Acacia Research Corp Earnings Call
Every investor in Acacia Research Corporation (NASDAQ:ACTG) should be aware of the most powerful shareholder groups...
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat the S&P […]
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We...
Q2 2019 Acacia Research Corp Earnings Call
NEW YORK--(BUSINESS WIRE)--Acacia Research Corporation (NASDAQ: ACTG) announced today it will release its first quarter financial results on Monday, May 11, 2020 at 8:00 a.m. ET/ 5:00 a.m. PT. The Company will host a conference call on the same day to discuss…
Acacia Research Corporation (NASDAQ: ACTG) ("Acacia" or the "Company") today announced that the two leading independent proxy advisory firms -- Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis") -- have recommended that stockholders vote "FOR" all proposals related to a strategic partnership (the "Transaction") with Starboard Value LP ("Starboard"), including the proposal to approve the voting and issuance of securities in connection with the Transaction without giving effect to any limitations under the rules of the Nasdaq Stock Market LLC, as well as an amendment to Acacia's Certificate of Incorporation to increase the number of authorized shares of common stock from 100 million to 300 million, each as set forth in the definitive proxy statement filed with the Securities and Exchange Commission on January 17, 2020 (the "Proxy Statement"). The proposals will be considered at a special meeting of stockholders scheduled for February 14, 2020 (the "Special Meeting").
(University of California - Los Angeles Health Sciences) The AIDS Clinical Trials Group (ACTG) has initiated a clinical trial to evaluate whether the drug combination hydroxychloroquine and azithromycin can prevent hospitalization and death from COVID-19
A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from COVID-19, the National Institutes of Health reports.
NEW YORK--(BUSINESS WIRE)--Acacia Research Corporation (“we”, "Acacia" or "the Company") (Nasdaq: ACTG) today reported results for the three-month period ended March 31, 2020. Clifford Press, Chief Executive Officer, stated, “Acacia has made significant progr…
As I mentioned in Friday's column, deep value investors are finding the pickings slim among net/nets (companies trading below net current asset value). The stock currently trades at just .59x net current asset value (or NCAV), .6x tangible book value, and ended its latest quarter with nearly $50 million, or $3.79 per share in cash and no debt. Currently trading at .88x NCAV, the company ended its latest quarter with $181.5 million, or $3.65 per share in cash and securities, and no debt.
Patients given the malaria drug touted by President Donald Trump as a potential treatment for COVID-19 did not improve significantly over those who did not, according to two new studies published in the medical journal BMJ on Thursday.
PHILADELPHIA, PA / ACCESSWIRE / December 16, 2019 / Kaskela Law LLC announces investigation of Acacia Research Corporation ("Acacia") (NASDAQ:ACTG) on behalf of the company's stockholders. The ...
NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Acacia Research Corp. (NASDAQ:ACTG) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at 11:00 ...
The National Institutes of Health have launched a placebo-controlled trial testing the safety and efficacy of hydroxychloroquine and azithromycin as a treatment for COVID-19.
Acacia Research Corporation ("we", "Acacia" or "the Company") (Nasdaq: ACTG) today reported results for the three-month period ended March 31, 2020.
Acacia Research Reports Fourth Quarter and Full Year 2019 Financial Results
Before we spend days researching a stock idea we like to take a look at how hedge funds and billionaire investors recently traded that stock. Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018. This means hedge funds […]
Acacia Research reported 2020 first quarter results on May 11th. Revenue improved respectably year-over-year by over 12%. But, the loss on the bottom line tripled.Acacia's strategic partnership with Starboard Value appears fruitful. In just four months of 202…
Funding Opportunity PA-20-149 from the NIH Guide for Grants and Contracts. The goals of this Funding Opportunity Announcement (FOA) are to stimulate further research on delineating the pathophysiology of HIV-1 associated CNS disease in the setting of chronic …
(Reuters) - Patients given the malaria drug touted by President Donald Trump as a potential treatment for COVID-19 did not improve significantly over those who did not, according to two new studies published in the medical journal BMJ on Thursday.
Funding Opportunity PA-20-151 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research grant applications studying mechanisms of HIV-1 persistence and eradication strategies specifically focused on the central …
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AIDS--U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Pomalyst® (pomalidomide) for AIDS-Related and HIV-Negative Kaposi sarcoma